January 09, 2025

curATime is looking for partners!

curATime is looking for partners!
Go back

The curATime cluster is one of 14 pioneering “Clusters4Future” initiatives funded by the German Federal Ministry of Education and Research (BMBF). Its mission is to promote personalized approaches to combat atherothrombosis-related diseases and to establish the Rhine-Main-Palatinate region as an international driver of innovation.

For the planned second implementation phase, the cluster is seeking new partners from science and industry who share its passion for revolutionary research in the field of cardiovascular diseases. It welcomes companies and institutions that can complement its existing expertise in artificial intelligence and mRNA technology and wish to actively contribute to the success of the cluster.

The curATime cluster aims to develop the next generation of medical solutions and revolutionise patient care!
Contact them for more information:

curatime@tron-mainz.de
curATime Cluster – Werden Sie Partner!Download

Our latest News

discover more
Cardiac Arrhythmias: New Defibrillator System Expands Treatment Options at UKHD

Cardiac Arrhythmias: New Defibrillator System Expands Treatment Options at UKHD

At Heidelberg University Hospital (UKHD), there is a new treatment option for certain patients with severe cardiac arrhythmias: an implantable defibrillator in which the electrode—unlike in conventional defibrillators—is placed outside the heart and blood vessels. This protects the blood vessels. In addition, the system can correct some arrhythmias using mild electrical impulses before an electric […]

read more
The Individual Genetic Background Shapes the Evolution of Cancer

The Individual Genetic Background Shapes the Evolution of Cancer

Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development. The findings, now published in Nature, provide new insights into […]

read more
Cell Signaling Technology Announces ISO 13485 Certification

Cell Signaling Technology Announces ISO 13485 Certification

Certification enables increased support for partners and customers with industry-leading antibody reagents for commercial applications. Danvers, MA, USA, July 16, 2026–Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced that its Beverly, MA, US and Leiden, NL facilities have achieved ISO 13485:2016 certification for […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp